Literature DB >> 20049445

Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome.

Donato Rigante1, Piero Valentini, Daniela Rizzo, Andrea Leo, Gabriella De Rosa, Roberta Onesimo, Alessia De Nisco, Donatella Francesca Angelone, Adele Compagnone, Angelica Bibiana Delogu.   

Abstract

Clues to predict the response to intravenous immunoglobulins (IVIG) and the development of coronary artery abnormalities (CAA) in children with Kawasaki syndrome (KS) are still undefined. We examined retrospectively the medical charts of children hospitalized between February 1990 and April 2009 with diagnosis of KS. A total of 32 Italian patients with a mean age of 23.8 months were analyzed and all received IVIG according to two schemes: 0.4 g/(kg day) for 5 days or 2 g/kg in a single infusion, combined with oral acetylsalicylic acid. General, clinical and laboratory data were registered. Each patient was evaluated with echocardiography at admission, then with 3-day and weekly frequency, respectively, during hospital stay and for the first 6-8 weeks since onset, and finally with a regular 6-12 month follow-up over time, according to patient risk stratification. Five patients showing significantly higher values of C-reactive protein (CRP) at admission were IVIG-resistant after the first infusion (P = 0.04) in comparison with the remaining 27. Five patients out of 32 developed CAA, with no statistical significance when analyzed for IVIG dosage or IVIG-resistance. The demonstration of CAA was significantly higher in children aged <12 months (P = 0.037). Our experience, limited to a single-center cohort of 32 patients with KS, though treated with two different IVIG schemes, has shown that higher values of CRP and younger age at onset are nodal points in determining, respectively, a failure in the response to IVIG and an increased occurrence of CAA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20049445     DOI: 10.1007/s00296-009-1337-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  27 in total

1.  The treatment of Kawasaki syndrome with intravenous gamma globulin.

Authors:  J W Newburger; M Takahashi; J C Burns; A S Beiser; K J Chung; C E Duffy; M P Glode; W H Mason; V Reddy; S P Sanders
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

2.  Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.

Authors:  Kimiyasu Egami; Hiromi Muta; Masahiro Ishii; Kenji Suda; Yoko Sugahara; Motofumi Iemura; Toyojiro Matsuishi
Journal:  J Pediatr       Date:  2006-08       Impact factor: 4.406

3.  HLA antigens in Kawasaki disease.

Authors:  S Kato; M Kimura; K Tsuji; S Kusakawa; T Asai; T Juji; T Kawasaki
Journal:  Pediatrics       Date:  1978-02       Impact factor: 7.124

4.  [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

Authors:  T Kawasaki
Journal:  Arerugi       Date:  1967-03

5.  Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006.

Authors:  Wen-Chan Huang; Li-Min Huang; I-Shou Chang; Luan-Yin Chang; Bor-Luen Chiang; Pei-Jer Chen; Mei-Hwan Wu; Hung-Chi Lue; Chun-Yun Lee
Journal:  Pediatrics       Date:  2009-02-23       Impact factor: 7.124

Review 6.  Kawasaki disease: diagnosis, management, and long-term implications.

Authors:  Gary M Satou; Joseph Giamelli; Michael H Gewitz
Journal:  Cardiol Rev       Date:  2007 Jul-Aug       Impact factor: 2.644

Review 7.  Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications.

Authors:  G De Rosa; M Pardeo; D Rigante
Journal:  Eur Rev Med Pharmacol Sci       Date:  2007 Sep-Oct       Impact factor: 3.507

8.  Kawasaki syndrome hospitalizations in the United States, 1997 and 2000.

Authors:  Robert C Holman; Aaron T Curns; Ermias D Belay; Claudia A Steiner; Lawrence B Schonberger
Journal:  Pediatrics       Date:  2003-09       Impact factor: 7.124

9.  Guidelines for long-term management of patients with Kawasaki disease. Report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  A S Dajani; K A Taubert; M Takahashi; F Z Bierman; M D Freed; P Ferrieri; M Gerber; S T Shulman; A W Karchmer; W Wilson
Journal:  Circulation       Date:  1994-02       Impact factor: 29.690

10.  Epidemiologic features of Kawasaki disease in Japan: results from the nationwide survey in 2005-2006.

Authors:  Yosikazu Nakamura; Mayumi Yashiro; Ritei Uehara; Izumi Oki; Makoto Watanabe; Hiroshi Yanagawa
Journal:  J Epidemiol       Date:  2008-07-18       Impact factor: 3.211

View more
  35 in total

Review 1.  Non-infectious makers of Kawasaki syndrome: tangible or elusive triggers?

Authors:  Donato Rigante; Giusyda Tarantino; Piero Valentini
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

Review 2.  Treatment of Kawasaki disease by different doses of immunoglobulin: a meta analysis of efficacy and safety.

Authors:  Jing Chen; Bin Ma; Li-Xing Lin; Yi-Ming Xue
Journal:  Transl Pediatr       Date:  2012-10

3.  Severe vitamin D deficiency in patients with Kawasaki disease: a potential role in the risk to develop heart vascular abnormalities?

Authors:  Stefano Stagi; Donato Rigante; Gemma Lepri; Marco Matucci Cerinic; Fernanda Falcini
Journal:  Clin Rheumatol       Date:  2015-05-22       Impact factor: 2.980

4.  Prediction of intravenous immunoglobulin resistance in Kawasaki disease in an East China population.

Authors:  Yunjia Tang; Wenhua Yan; Ling Sun; Jie Huang; Weiguo Qian; Yueyue Ding; Haitao Lv
Journal:  Clin Rheumatol       Date:  2016-08-05       Impact factor: 2.980

Review 5.  Delayed diagnosis of Kawasaki syndrome and thrombosis of a medium-sized aneurysm of the anterior descending coronary artery: case report and literature review.

Authors:  Gabriella De Rosa; Maria Giuseppina Cefalo; Riccardo Marano; Marco Piastra; Angelica Bibiana Delogu; Donato Rigante
Journal:  Rheumatol Int       Date:  2011-02-16       Impact factor: 2.631

6.  Epidemiologic survey of Kawasaki disease in Inner Mongolia, China, between 2001 and 2013.

Authors:  Xiaomei Zhang; Yanyan Liang; Wanyu Feng; Xuewen Su; Hua Zhu
Journal:  Exp Ther Med       Date:  2016-05-26       Impact factor: 2.447

7.  The prognostic role of abnormal liver function in IVIG unresponsiveness in Kawasaki disease: a meta-analysis.

Authors:  Ling Liu; Wei Yin; Ruigeng Wang; Dongming Sun; Xuelian He; Yan Ding
Journal:  Inflamm Res       Date:  2015-12-08       Impact factor: 4.575

Review 8.  Management of Small Vessel Vasculitides.

Authors:  Giuseppe Lopalco; Donato Rigante; Vincenzo Venerito; Giacomo Emmi; Maria Grazia Anelli; Giovanni Lapadula; Florenzo Iannone; Luca Cantarini
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

9.  Epidemiology and risk factors for coronary artery abnormalities in children with complete and incomplete Kawasaki disease during a 10-year period.

Authors:  Georgia Giannouli; Chryssa Tzoumaka-Bakoula; Ioannis Kopsidas; Paraskevi Papadogeorgou; George P Chrousos; Athanasios Michos
Journal:  Pediatr Cardiol       Date:  2013-03-06       Impact factor: 1.655

10.  Pro-brain natriuretic peptide (ProBNP) levels in North Indian children with Kawasaki disease.

Authors:  Mounika Reddy; Surjit Singh; Amit Rawat; Avinash Sharma; Deepti Suri; Manoj Kumar Rohit
Journal:  Rheumatol Int       Date:  2016-02-05       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.